Sarah Crabtree
Algemeen Adviseur bij Syncona Partners LLP
Oorsprong van het eerstegraads netwerk van Sarah Crabtree
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
30
| Subsidiary | Investment Managers | 30 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Sarah Crabtree via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Private Equity Investor | |
| Forcefield Therapeutics Ltd. | Chairman Director/Board Member Chief Executive Officer Director/Board Member | ||
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman Consultant / Advisor | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman Chairman Director/Board Member | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Operating Officer | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree | |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Founder Director/Board Member | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| University College London | College/University | Undergraduate Degree Undergraduate Degree | |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor | |
Canbex Therapeutics Ltd.
 Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
| Syncona Ip Holdco Ltd. | Director/Board Member | ||
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Director/Board Member | |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Salvia BioElectronics BV
 Salvia BioElectronics BV BiotechnologyHealth Technology Salvia BioElectronics BV develops a bioelectronics therapy for people suffering from chronic neurological diseases. The company was founded by Sjaak Deckers and Hubert Martens in 2017 and is headquartered in Eindhoven, the Netherlands. | Biotechnology | Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member | |
Calypso Biotech SA
 Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Draupnir Bio ApS
 Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
| F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member | |
| TRANSLATE BIO, INC. | Biotechnology | Director/Board Member | |
Aveni SA
 Aveni SA Chemicals: Major DiversifiedProcess Industries Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France. | Chemicals: Major Diversified | Director/Board Member | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
| Aalto University School of Business | College/University | Masters Business Admin | |
| University of Leiden | College/University | Graduate Degree | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
iOnctura SA
 iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Verenigd Koninkrijk | 23 |
| Verenigde Staten | 11 |
| Zwitserland | 7 |
| Nederland | 7 |
| Denemarken | 3 |
Sectoraal
| Health Technology | 32 |
| Consumer Services | 7 |
| Commercial Services | 7 |
| Finance | 3 |
| Miscellaneous | 2 |
Operationeel
| Director/Board Member | 106 |
| Private Equity Investor | 35 |
| Chairman | 30 |
| Corporate Officer/Principal | 25 |
| Undergraduate Degree | 17 |
Sterkste connecties
| Insiders | |
|---|---|
| Martin Murphy | 33 |
| Ken Galbraith | 30 |
| Roel Bulthuis | 29 |
| Chris Hollowood | 19 |
| Hitesh Thakrar | 14 |
| Lisa Bright | 13 |
| Dominic Schmidt | 12 |
| Edward Hodgkin | 10 |
| Rolf Soderstrom | 10 |
| John Tsai | 10 |
| Elisa Petris | 7 |
| Ben Woolven | 6 |
| Alex Hamilton | 6 |
| Magdalena Jonikas | 5 |
| Dear Freddie | 5 |
- Beurs
- Insiders
- Sarah Crabtree
- Bedrijfsconnecties
